Multiple independent studies in cellular and mouse models have demonstrated that sustained, or incompletely inhibited, mTORC1 signaling can contribute to TKI resistance in EGFR-mutant NSCLC and BRAF-mutant melanoma28. Here, BRAF is linked to non-small cell lung carcinoma.